Published in J Clin Oncol on January 20, 2005
Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy (ACCEPT) | NCT01192087
Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol (2009) 1.65
MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol (2011) 1.61
Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS One (2009) 1.49
Adenoid cystic carcinoma of the tongue--clinicopathological study and survival analysis. Head Neck Oncol (2009) 1.47
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol (2011) 1.21
Salivary gland carcinomas. Oral Maxillofac Surg (2012) 1.20
New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle (2010) 1.16
Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol (2005) 1.07
Molecular biology of adenoid cystic carcinoma. Head Neck (2011) 1.07
Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications. Cancer (2010) 1.01
Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia (2010) 0.95
RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab. Radiat Oncol (2010) 0.93
Salivary gland cancer stem cells. Oral Oncol (2013) 0.92
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck (2009) 0.92
Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy]. BMC Cancer (2011) 0.90
Evaluation of c-kit protein (CD117) expression in common salivary gland neoplasms. J Oral Maxillofac Pathol (2014) 0.89
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology (2013) 0.88
Treatment of c-kit positive adenoid cystic carcinoma of the tongue: A case report. Oncol Lett (2014) 0.88
Prognostic value of expression of molecular markers in adenoid cystic cancer of the salivary glands compared with lymph node metastasis: a retrospective study. World J Surg Oncol (2012) 0.86
MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. Am J Cancer Res (2015) 0.86
Concern Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol (2012) 0.86
Adenoid cystic carcinoma of the parotid gland. Contemp Clin Dent (2012) 0.85
Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget (2015) 0.85
Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer (2013) 0.84
Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved. Eur Arch Otorhinolaryngol (2008) 0.84
Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget (2015) 0.83
Oncocytoma of the parotid gland: a case report and review of the literature. Case Rep Oncol (2014) 0.82
TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. Transl Oncol (2008) 0.81
Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer. Int J Otolaryngol (2011) 0.80
The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer (2013) 0.80
Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy. Biomed Res Int (2015) 0.79
Primary pulmonary adenoid cystic carcinoma: clinicopathological analyses of 12 cases. Int J Clin Exp Pathol (2015) 0.78
c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands. Transl Oncol (2014) 0.78
Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. J Med Case Rep (2011) 0.77
New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am (2008) 0.75
A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer (2014) 0.75
Parotid carcinoma: Current diagnostic workup and treatment. Indian J Surg Oncol (2010) 0.75
Primary intraosseous ACC of mandible of possible salivary origin: A rare clinical entity. Int J Surg Case Rep (2014) 0.75
Management of salivary gland carcinomas - a review. Oncotarget (2016) 0.75
Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas. Clin Oral Investig (2015) 0.75
A Phase II study of Dovitinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res (2017) 0.75
[Salivary gland-like tumors of the breast]. Pathologe (2006) 0.75
Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands. Virchows Arch (2015) 0.75
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum (2002) 4.23
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
The statins as anticancer agents. Clin Cancer Res (2003) 3.36
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol (2005) 3.34
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis (2004) 3.11
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 2.64
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst (2012) 2.57
Medication reconciliation at hospital discharge: evaluating discrepancies. Ann Pharmacother (2008) 2.57
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst (2012) 2.46
Impact of wait times on survival for women with uterine cancer. J Clin Oncol (2013) 2.45
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Nasopharyngeal carcinoma: the next challenges. Eur J Cancer (2010) 2.04
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol (2007) 1.84
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
Designing transformative clinical trials in the cancer genome era. J Clin Oncol (2013) 1.79
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol (2005) 1.76
Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab (2002) 1.73
Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol (2003) 1.71
First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol (2008) 1.70
Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol (2005) 1.69
Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review. J Clin Oncol (2011) 1.66
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol (2009) 1.64
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res (2006) 1.63
The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol (2002) 1.60
Pharmacist medication assessments in a surgical preadmission clinic. Arch Intern Med (2007) 1.57
Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther (2005) 1.57
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging (2004) 1.54
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol (2007) 1.53
Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer (2002) 1.49
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer (2012) 1.49
Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.49
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.44
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res (2008) 1.43
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res (2008) 1.42
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol (2008) 1.42
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer (2006) 1.41
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol (2012) 1.38
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer (2007) 1.37
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res (2010) 1.35
Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer (2006) 1.33
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol (2010) 1.31
Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol (2005) 1.31
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol (2011) 1.29
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol (2006) 1.29
Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin (2007) 1.29
MET as a target for treatment of chest tumors. Lung Cancer (2008) 1.29
Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol (2007) 1.28
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer (2007) 1.27
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res (2007) 1.26